10-Q · May 7, 2026
Genelux Corporation reported a challenging quarter with no revenue generation, resulting in a net loss of $8.9 million, worsening from a loss of $7.5 million year-over-year. Operating expenses increased by approximately…
Earnings analysis · 10-Q
GNLX earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q does not include the income statement, balance sheet or cash-flow statements, so current-quarter revenue, margins, EPS, cash burn and segment trends cannot be assessed from the available filing text.…
Read full summary
The extracted 10-Q does not include the income statement, balance sheet or cash-flow statements, so current-quarter revenue, margins, EPS, cash burn and segment trends cannot be assessed from the available filing text. Management reported effective disclosure controls as of June 30, 2026 and no material changes in internal controls. The principal filing update was a new trade-policy risk, including potential 100% tariffs on certain pharmaceutical products and ingredients; no quantitative outlook was provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls Remained Effective
Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026.
-
No Material Control Changes
The company reported no changes during the period covered by the 10-Q that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
What to watch
-
Potential 100% Pharmaceutical Tariffs
The company added a material risk related to international trade policies. It stated that a presidential proclamation will impose 100% tariffs on certain patented pharmaceutical products and associated ingredients, potentially increasing R&D costs, disrupting supply chains and delaying development timelines.
Management's outlook
No quantitative revenue or EPS outlook was provided in the extracted 10-Q; no change to prior guidance can be determined.
Earlier filings 4
10-K · March 19, 2026
Genelux is a late-stage oncolytic viral immunotherapy company advancing Olvi-Vec through a registrational Phase 3 (OnPrime/GOG-3076) in platinum-resistant/refractory ovarian cancer and ongoing systemic trials in NSCLC…
10-Q · November 5, 2025
Genelux reported Q3 2025 GAAP net loss of $7,950 and EPS of $(0.21), slightly ahead of consensus $(0.22). Revenue remained $0 for the quarter; operating expenses rose to $8,194 driven by higher R&D and G&A. Management…
10-Q · August 7, 2025
Genelux reported Q2 2025 net loss of $7,456,000 (GAAP loss per share $0.20) on revenue of $0.00. Operating expenses increased to $7,792,000 for the quarter (R&D $4,758,000; G&A $3,034,000). As of June 30, 2025 the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.